Shilpa Medicare Limited

Equities

SHILPAMED

INE790G01031

Pharmaceuticals

Market Closed - Bombay S.E. 06:00:53 2024-07-12 am EDT 5-day change 1st Jan Change
659.6 INR -1.01% Intraday chart for Shilpa Medicare Limited -0.07% +99.62%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Shilpa Medicare Arm's API Facility in Karnataka, India, Passes Brazilian Drug Regulator's Inspection MT
Shilpa Medicare to Receive Shares from Unit as Loan Payment MT
Transcript : Shilpa Medicare Limited - Shareholder/Analyst Call
Shilpa Medicare Shares Rally 16% as Client Reports Positive Clinical Trial Results MT
INDIA STOCKS-HDFC Bank drags Indian shares as rally to record highs takes pause RE
Unicycive Therapeutics, Inc. Enters into First Amendment to Manufacturing and Supply Agreement with Shilpa Medicare, Ltd CI
Shilpa Medicare Bio Analytical Unit Gets "No Action Indicated" Classification from US FDA MT
Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024
Shilpa Medicare Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024 CI
Shilpa Medicare Limited Announces Successful Completion of Early Clinical Development and Ongoing Phase 3 Clinical Trial of Its Newly Developed Drug "SML-007", for the Treatment of Non-Alalcoholic Fatty Liver Disease CI
Shilpa Medicare Partner Amneal Pharma Launches Ready-to-Use Pemetrexed in US MT
Shilpa Medicare Gets GMP Certification from Austrian Agency for Telangana, India Unit MT
Shilpa Medicare Gets Board Nod to Launch QIP MT
Shilpa Medicare's Life Science Arm Names CEO MT
Shilpa Medicare's New Unit in Hyderabad, India Gets Zero Observations from US FDA MT
Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe MT
Transcript : Shilpa Medicare Limited, Q3 2024 Earnings Call, Feb 12, 2024
Shilpa Medicare Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Shilpa Medicare Gets Germany's Marketing Approval for Rare Muscles Diseases Drug MT
Shilpa Medicare Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Shilpa Medicare Acquires US-Based Pilnova Pharma MT
Shilpa Medicare Limited Launches Naturally Derived Option for the Treatment of Oral Mucositis in India Under the Brand Name Oraal CI
Shilpa Medicare Unit's API Manufacturing Plant Gets Clearance from Japanese Drug Regulator's Inspection MT
Shilpa Medicare Gets UK Drug Regulator's Nod to Market Drug for Meniere's Syndrome Symptoms MT
Shilpa Medicare Limited Receives Marketing Authorization from MHRA, UK, for Betahistine Dihydrochloride Orodispersible Films, 24 mg CI
Chart Shilpa Medicare Limited
More charts
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.
More about the company

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. SHILPAMED Stock
  4. News Shilpa Medicare Limited
  5. Shilpa Medicare Gets Approval to Market Smoking Cessation Drug in Europe